サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1316804

脳腫瘍診断薬市場：検査タイプ別、脳腫瘍タイプ別-2023-2030年の世界予測

Brain Cancer Diagnostics Market by Test Type, Brain Cancer Type - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 181 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
脳腫瘍診断薬市場：検査タイプ別、脳腫瘍タイプ別-2023-2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 181 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

脳腫瘍診断薬の世界市場は、2023年に40億2,343万米ドル、CAGR12.42%で大きく成長し、2030年には91億4,340万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の脳腫瘍診断薬市場を評価するために不可欠です。事業戦略や製品満足度などの主要指標を検証することで、ベンダーの包括的な評価を提供し、ユーザーが特定のニーズに基づいて情報に基づいた意思決定を行えるようにします。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.脳腫瘍診断薬の世界市場規模および予測は？

2.予測期間中、世界の脳腫瘍診断薬市場を形成するCOVID-19の阻害要因と影響は？

3.脳腫瘍診断薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.脳腫瘍診断薬の世界市場における競争戦略は？

5.脳腫瘍診断薬の世界市場における技術動向と規制の枠組みは？

6.脳腫瘍診断薬の世界市場における主要ベンダーの市場シェアは？

7.脳腫瘍診断薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 脳腫瘍の発生率の増加
      • 民間診断センターの数の増加と官民パートナーシップの増加
    • 抑制要因
      • 診断に伴う多額の費用と診断に対する意識の低さ
    • 機会
      • 診断装置の技術進歩
      • さまざまながん変異に対する診断法の開発
    • 課題
      • 高放射線被ばくのリスクの高まりと厳格な規制ガイドライン
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 脳腫瘍診断薬市場テストタイプ別

  • 磁気共鳴画像
  • 磁気共鳴分光法
  • PETスキャン
  • スパイナルタップ

第7章 脳腫瘍診断薬市場脳腫瘍の種類別

  • 聴神経腫
  • 星状細胞腫
  • 脊索腫
  • 上衣腫

第8章 南北アメリカの脳腫瘍診断薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の脳腫瘍診断薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの脳腫瘍診断薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第12章 掲載企業一覧

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. BRAIN CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2022 VS 2030 (%)
  • FIGURE 5. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2022 VS 2030 (%)
  • FIGURE 6. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 7. BRAIN CANCER DIAGNOSTICS MARKET DYNAMICS
  • FIGURE 8. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. BRAIN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 15. BRAIN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. BRAIN CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE SPECTROSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SPINAL TAP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 10. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CHORDOMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EPENDYMOMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. BRAIN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 101. BRAIN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 102. BRAIN CANCER DIAGNOSTICS MARKET LICENSE & PRICING
目次
Product Code: MRR-A26E0E57413E

The Global Brain Cancer Diagnostics Market is forecasted to grow significantly, with a projected USD 4,023.43 million in 2023 at a CAGR of 12.42% and expected to reach a staggering USD 9,143.40 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Brain Cancer Diagnostics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Brain Cancer Diagnostics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Test Type, market is studied across Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, PET Scan, and Spinal Tap. The PET Scan is projected to witness significant market share during forecast period.

Based on Brain Cancer Type, market is studied across Acoustic Neuroma, Astrocytomas, Chordomas, and Ependymomas. The Ependymomas is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Brain Cancer Diagnostics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Brain Cancer Diagnostics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Brain Cancer Diagnostics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Brain Cancer Diagnostics Market?

4. What is the competitive strategic window for opportunities in the Global Brain Cancer Diagnostics Market?

5. What are the technology trends and regulatory frameworks in the Global Brain Cancer Diagnostics Market?

6. What is the market share of the leading vendors in the Global Brain Cancer Diagnostics Market?

7. What modes and strategic moves are considered suitable for entering the Global Brain Cancer Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Brain Cancer Diagnostics Market, by Test Type, 2022 vs 2030
  • 4.3. Brain Cancer Diagnostics Market, by Brain Cancer Type, 2022 vs 2030
  • 4.4. Brain Cancer Diagnostics Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of brain cancer
      • 5.1.1.2. Growth in the number of private diagnostic centers and rising public-private partnerships
    • 5.1.2. Restraints
      • 5.1.2.1. Heavy costs associated with diagnosis and low awareness about the diagnosis
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement in diagnostics devices
      • 5.1.3.2. Development of diagnostic approaches for various cancer mutations
    • 5.1.4. Challenges
      • 5.1.4.1. Rising risk of high radiation exposure and stringent regulatory guidelines
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Brain Cancer Diagnostics Market, by Test Type

  • 6.1. Introduction
  • 6.2. Magnetic Resonance Imaging
  • 6.3. Magnetic Resonance Spectroscopy
  • 6.4. PET Scan
  • 6.5. Spinal Tap

7. Brain Cancer Diagnostics Market, by Brain Cancer Type

  • 7.1. Introduction
  • 7.2. Acoustic Neuroma
  • 7.3. Astrocytomas
  • 7.4. Chordomas
  • 7.5. Ependymomas

8. Americas Brain Cancer Diagnostics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Brain Cancer Diagnostics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Brain Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing